Phase ii study of whole brain radiotherapy with or without erlotinib in patients with multiple brain metastases from lung adenocarcinoma

Drug Design, Development and Therapy

Volumn 7, Issue , 2013, Pages 1179-1186

  Zhuang, Hongqing ^a,b,c   Yuan, Zhiyong ^a,b,c   Wang, Jun ^a,b,c   Zhao, Lujun ^a,b,c   Pang, Qingsong ^a,b,c   Wang, Ping ^a,b,c  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b KEY LABORATORY OF CANCER PREVENTION AND THERAPY   (China)

^c Tianjin Lung Cancer Center   (China)

Author keywords

Erlotinib; Radiosensitizer; Tyrosine kinase inhibitor; WBRT

Indexed keywords

DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; PEMETREXED;

ADULT; AGED; ANOREXIA; ARTICLE; BLOOD BRAIN BARRIER; BLOOD TOXICITY; BRAIN METASTASIS; BRAIN RADIATION; CANCER CONTROL; CANCER PROGNOSIS; CHEILITIS; COHORT ANALYSIS; CONJUNCTIVITIS; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRY SKIN; DYSPEPSIA; DYSPNEA; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HEADACHE; HUMAN; KARNOFSKY PERFORMANCE STATUS; LOCAL PROGRESSION FREE SURVIVAL; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MUCOSA INFLAMMATION; NAIL DISEASE; NAUSEA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PRURITUS; RADIATION DERMATITIS; RADIATION DOSE; RADIATION INJURY; RADIATION RESPONSE; RASH; SIDE EFFECT; SKIN DISEASE; STOMATITIS; SURVIVAL; SURVIVAL TIME; TASTE DISORDER; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION; WILD TYPE; XEROPHTHALMIA;

ERLOTINIB; RADIOSENSITIZER; TYROSINE KINASE INHIBITOR; WBRT;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; COHORT STUDIES; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; PROSPECTIVE STUDIES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 84885224003     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S53011     Document Type: Article

References (24)

1. Tsao MN, Lloyd N, Wong R, Chow E, Rakovitch E, Laperriere N. Whole brain radiotherapy for the treatment of multiple brain metastases. Cochrane Database Syst Rev. 19, 2006;(3):CD003869.
2. Kawabe T, Phi JH, Yamamoto M, Kim DG, Barfod BE, Urakawa Y. Treatment of brain metastasis from lung cancer. Prog Neurol Surg. 2012;25:148-155.
3. Kim JE, Lee DH, Choi Y, et al. Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis. Lung Cancer. 2009;65(3):351-354.
4. Gounant V, Wislez M, Poulot V, et al. Subsequent brain metastasis responses to epidermal growth factor receptor tyrosine kinase inhibitors in a patient with non-small-cell lung cancer. Lung Cancer. 2007;58(3): 425-428.
5. Olmez I, Donahue BR, Butler JS, Huang Y, Rubin P, Xu Y. Clinical outcomes in extracranial tumor sites and unusual toxicities with concurrent whole brain radiation (WBRT) and Erlotinib treatment in patients with non-small cell lung cancer (NSCLC) with brain metastasis. Lung Cancer. 2010;70(2):174-179.
6. Lind JS, Lagerwaard FJ, Smit EF, Senan S. Phase I study of concurrent whole brain radiotherapy and erlotinib for multiple brain metastases from non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2009; 74(5):1391-1396.
7. Yi HG, Kim HJ, Kim YJ, et al. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI. Lung Cancer. 2009;65(1):80-84.
8. Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13(3):176-181.
9. Palazzi M, Tomatis S, Orlandi E, et al. Effects of treatment intensification on acute local toxicity during radiotherapy for head and neck cancer: prospective observational study validating CTCAE, version 3.0, scoring system. Int J Radiat Oncol Biol Phys. 2008;70(2): 330-337.
10. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247.
11. Sun JM, Ahn MJ, Park MJ, et al. Accuracy of RECIST 1.1 for non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors. Lung Cancer. 2010;69(1):105-109.
12. Robinet G, Thomas P, Breton JL, et al. Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Français de Pneumo-Cancérologie (GFPC) Protocol 95-1. Ann Oncol. 2001;12(1):59-67.
13. Cortot AB, Gerinière L, Robinet G, et al; Groupe Lyon-Saint-Etienne d'Oncologie Thoracique; Groupe Français de Pneumo-Cancérologie. Phase II trial of temozolomide and cisplatin followed by whole brain radiotherapy in non-small-cell lung cancer patients with brain metastases: a GLOT-GFPC study. Ann Oncol. 2006;17(9):1412-1417.
14. Guerrieri M, Wong K, Ryan G, Millward M, Quong G, Ball DL. A randomised phase III study of palliative radiation with concomitant carboplatin for brain metastases from non-small cell carcinoma of the lung. Lung Cancer. 2004;46(1):107-111.
15. Togashi Y, Masago K, Fukudo M, et al. Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer. J Thorac Oncol. 2010;5(7):950-955.
16. Broniscer A, Panetta JC, O'Shaughnessy M, et al. Plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite OSI-420. Clin Cancer Res. 2007;13(5):1511-1515.
17. O'Connor MM, Mayberg MR. Effects of radiation on cerebral vasculature: a review. J Neurosurgery. 2000;46(1):138-149.
18. Hutchinson F. Molecular biology of mutagenesis of mammalian cells by ionizing radiation. Semin Cancer Biol. 1993;4(2):85-92.
19. Harms-Ringdahl M, Nicotera P, Radford IR. Radiation induced apoptosis. Mutat Res. 1996;366(2):171-179.
20. Chinnaiyan P, Huang S, Vallabhaneni G, et al. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res. 2005;65(8): 3328-3335.
21. Halatsch ME, Löw S, Mursch K, et al. Candidate genes for sensitivity and resistance of human glioblastoma multiforme cell lines to erlotinib. Laboratory investigation. J Neurosurg. 2009;111(2):211-218.
22. Ciuleanu T, Stelmakh L, Cicenas S, et al. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol. 2012;13(3):300-308.
23. Welsh JW, Komaki R, Amini A, et al. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J Clin Oncol. 2013;31(7): 895-902.
24. Porta R, Sánchez-Torres JM, Paz-Ares L, et al. Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation. Eur Respir J. 2011;37(3):624-631.